Good news comes in twos for Topcon

Article

Topcon Medical Systems has received FDA approval for its 3D OCT-1000. Meanwhile, the firm has also announced that it is to become the sole European distributor of OptiMedica's Pascal Photocoagulator.

Topcon Medical Systems has received FDA approval for its 3D OCT-1000. Meanwhile, the firm has also announced that it is to become the sole European distributor of OptiMedica's Pascal Photocoagulator.

The 3D OCT-1000 is the first Fourier-domain optical coherence tomography (OCT) with a colour, non-mydriatic retinal camera. It is designed to provide high-resolution cross sectional imaging of the retina to aid in the diagnosis and monitoring of various pathologies, including retinal detachments, macula holes, age-related macular degeneration and glaucoma.

Topcon has also entered into an agreement with OptiMedica whereby Topcon Europe Medical B.V., the European subsidiary of the Topcon Corporation, is to become the exclusive distributor of the Pascal Photocoagulator in key European markets.

The Pascal (Pattern Scan Laser) Photocoagulator is a device that has been designed to optimize the treatment of eye diseases by applying a predetermined pattern array of up to 56 laser spots to the retina within 0.6 seconds.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.